Development of the Theta Comparative Cell Scoring Method to Quantify Diverse Phenotypic Responses Between Distinct...

Area of Science:

• Pharmacogenomics
• Cellular Biology
• Biomedical Data Science

Background:

• High-throughput screening is crucial for drug discovery.
• Understanding compound-induced cellular phenotypes is key to personalized medicine.
• Current methods lack efficient ways to correlate phenotypic data with molecular profiles.

Purpose of the Study:

• To develop novel data visualization tools and a Theta comparative cell scoring (TCCS) method.
• To enable high-throughput in vitro pharmacogenomic studies using multiparametric high-content analysis.
• To support the identification of biomarkers and elucidate drug mechanisms of action.

Main Methods:

• Development of novel data visualization tools.
• Implementation of the Theta comparative cell scoring (TCCS) method.
• Application of TCCS to multiparametric high-content analysis of diverse cellular phenotypes.

Main Results:

• The TCCS method provides a univariate descriptor of divergent compound-induced phenotypic responses.
• Proof-of-principle data quantified distinct phenotypic responses between eight breast cancer cells representing four disease subclasses.
• Demonstrated correlation of phenotypic responses with genetic, epigenetic, and proteomic datasets is supported.

Conclusions:

• The developed methods facilitate personalized healthcare strategies without prior drug target knowledge.
• TCCS combined with advanced technologies can accelerate biomarker identification and personalized medicine.
• This approach is poised to advance personalized medicine across various diseases and therapeutics.